Pfizer PFE Biopharma — Cost of Sales

Similar metrics at other companies

BDXBioPharma Systems — Cost of products sold

$316M+3.3%

BAXPharmaceuticals — Cost of Sales

$458M+15.7%

ATRPharma — Cost of Sales (exclusive of depreciation and amortization):

$228.54M+11.4%

IFFHealth & Biosciences — Cost of Sales

$327M+9.7%

BDXBioPharma Systems — Segment Cost of Products and Services Sold as a Percent of Revenues

53.6%+0.4pp

CAHPharmaceutical and Specialty Solutions — Cost of products sold

$54.6B+11.0%

Questions, answered.

What is Pfizer's biopharma — cost of sales?

Pfizer (PFE) reported biopharma — cost of sales of $3.03B in Q1 2026.

How has Pfizer's biopharma — cost of sales changed year-over-year?

Pfizer's biopharma — cost of sales increased by 31.1% year-over-year, from $2.31B to $3.03B.

What is the long-term trend for Pfizer's biopharma — cost of sales?

Over 3 years (2022 to 2025), Pfizer's biopharma — cost of sales has grown at a -25.7% compound annual growth rate (CAGR), from $32.86B to $13.51B.

What does biopharma — cost of sales mean?

The direct costs attributable to the production and distribution of the biopharma segment's products, including raw materials, manufacturing labor, and logistics. It is a key determinant of the segment's gross margin.